Immuno-oncology targets
TARGET NAME | DISEASE INDICATIONS | CURRENT STATUS | PROJECTION |
---|---|---|---|
ZM008
*New target. Functions through NK cell based therapy |
Germinal B cell lymphoma, glioma, hepatocellular carcinoma, prostate cancer | In-vivo study completed | Preclinical study – 2018
Ph I study – 2019 |
ZM012
mAb target. Functions through tumour associated antigen/NK cell receptor |
Lymphoma and other Undisclosed indications | Unique Clone identification in process | Lead molecule – September, 2018 |
ZM014
mAb target. Functions through tumour NK cell receptor |
Lymphoma | Unique Clone identification in process | Lead molecule – September, 2018 |
2
Molecules for NK cell and cell targets under development
Future targets of interest